ACM
KYMR icon

AlphaCrest Capital Management’s Kymera Therapeutics KYMR Stock Holding History

AlphaCrest Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-19,076
Closed -$415K – 616
2022
Q3 		$415K Buy
+19,076
New +$503K 0.03% 1042
2022
Q1 		– Sell
-4,206
Closed -$267K – 1336
2021
Q4 		$267K Buy
+4,206
New +$245K 0.01% 1282

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

AlphaCrest Capital Management's KYMR Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Kymera Therapeutics (KYMR) in Q4 2022, closing a stake of 19,076 shares — an estimated $415K sold.

AlphaCrest Capital Management first reported a position in KYMR in Q4 2021 and held it in 2 quarters. The position peaked at $415K in Q3 2022. 121 funds tracked by Wall St. Rank hold KYMR as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Kymera Therapeutics position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 19,076 Kymera Therapeutics shares in Q4 2022, an estimated $415K.
  • AlphaCrest Capital Management first reported a position in Kymera Therapeutics in Q4 2021 and held it in 2 quarters.
  • AlphaCrest Capital Management's Kymera Therapeutics position peaked at $415K in Q3 2022.
  • 121 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.